Literature DB >> 17180526

Verteporfin therapy for neovascular age-related macular degeneration in Indian eyes.

Nazimul Hussain1, Taraprasad Das2, Rohit Khanna3, Kallukuri Sumasri2, Lakshmana Samudram Mohan Ram2.   

Abstract

PURPOSE: To determine visual outcome after a 12-month follow-up period of verteporfin therapy for subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in Indian patients.
METHODS: Twenty-five patients (26 eyes) who completed a 12-month follow-up after photodynamic therapy for subfoveal CNV secondary to AMD were included in the study. The follow-up schedule was every month for 2 months and then every 3 months thereafter until 12 months. Improvement in visual acuity was defined as a >or=10-letter gain, and deterioration as a >or=10-letter loss in the Early Treatment Diabetic Retinopathy Study chart at 4 m.
RESULTS: The mean age of the 25 patients was 62.3 +/- 9 years. There were 17 male patients (68%). The mean initial letter acuity was 28. 4 +/- 14.1, and the final letter acuity was 25.5 +/- 18.4 at 12 months. Initial visual acuity was >or=20/40 in seven eyes, 20/50-20/80 in nine eyes, and 20/100-20/200 in ten eyes; seven eyes had a >or=10-letter gain, and three eyes had a >or=10-letter loss. At the end of 12 months, six eyes had a >or=10-letter gain and ten eyes had a >or=10-letter loss.
CONCLUSION: Photodynamic therapy appears to preserve the vision in subfoveal CNV secondary to AMD in the eyes of Indian patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17180526     DOI: 10.1007/s10384-006-0367-4

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  11 in total

1.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

2.  Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.

Authors:  Neil M Bressler; Jennifer Arnold; Mustapha Benchaboune; Mark S Blumenkranz; Gary E Fish; Evangelos S Gragoudas; Hilel Lewis; Ursula Schmidt-Erfurth; Jason S Slakter; Susan B Bressler; Kelly Manos; Yong Hao; Laurie Hayes; John Koester; Al Reaves; H Andrew Strong
Journal:  Arch Ophthalmol       Date:  2002-11

Review 3.  Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.

Authors: 
Journal:  Retina       Date:  2005 Feb-Mar       Impact factor: 4.256

4.  Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.

Authors:  Mohammad Azab; David S Boyer; Neil M Bressler; Susan B Bressler; Ilona Cihelkova; Young Hao; Ilkka Immonen; Jennifer I Lim; Ugo Menchini; Joel Naor; Michael J Potter; Al Reaves; Philip J Rosenfeld; Jason S Slakter; Peter Soucek; H Andrew Strong; Andrea Wenkstern; Xiang Yao Su; Yit C Yang
Journal:  Arch Ophthalmol       Date:  2005-04

5.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Nazimul Hussain; Anjli Hussain; Sundaram Natarajan
Journal:  Indian J Ophthalmol       Date:  2005-06       Impact factor: 1.848

6.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

7.  Verteporfin therapy for myopic choroidal neovascularisation in Indian eyes (one year results).

Authors:  Nazimul Hussain; Taraprasad Das; Urvish Vashist; Kallukuri Sumashri
Journal:  Indian J Ophthalmol       Date:  2004-09       Impact factor: 1.848

8.  Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4.

Authors:  Gary S Rubin; Neil M Bressler
Journal:  Retina       Date:  2002-10       Impact factor: 4.256

9.  Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns.

Authors:  Ruth Axer-Siegel; Rita Ehrlich; Yuval Yassur; Irit Rosenblatt; Michal Kramer; Ethan Priel; Yoav Benjamini; Dov Weinberger
Journal:  Am J Ophthalmol       Date:  2004-02       Impact factor: 5.258

10.  Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Authors: 
Journal:  Am J Ophthalmol       Date:  2003-12       Impact factor: 5.258

View more
  3 in total

1.  Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jun-Kang Si; Kai Tang; Hong-Sheng Bi; Da-Dong Guo; Jun-Guo Guo; Yu-Xiang Du; Yan Cui; Xue-Mei Pan; Ying Wen; Xing-Rong Wang
Journal:  Int J Ophthalmol       Date:  2014-06-18       Impact factor: 1.779

2.  One-year results of verteporfin therapy for subretinal neovascularization associated with type 2A parafoveal telengiectasia.

Authors:  Nazimul Hussain; Taraprasad Das; Rohit Khanna; L S Mohan Ram; Kallukuri Sumasri
Journal:  Clin Ophthalmol       Date:  2007-12

3.  Two years follow-up outcome of verteporfin therapy for subfoveal choroidal neovascularization in pathologic myopia in Indian eyes.

Authors:  Nazimul Hussain; Rohit Khanna; Taraprasad Das; Raja Narayanan; Oluleye Tunji Sunday; Azad Gaurav Bansal; Rajeev Reddy
Journal:  Indian J Ophthalmol       Date:  2008 Nov-Dec       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.